NOT KNOWN FACTUAL STATEMENTS ABOUT SEMAGLUTIDE

Semaglutide continues to be shown to cause medullary thyroid mobile carcinoma in rodents. Whilst its clinical relevance to individuals is unknown, the FDA advises not to administer this drug in People with a personal or family background of medullary thyroid carcinoma. Semaglutide also poses a risk of pancreatitis and dehydration.Jillian Kubala, MS